conferenceseries.com

^{3rd International Conference on ANTIBODIES, BIO THERAPEUTICS & B2B & GENETIC AND PROTEIN ENGINEERING November 08-09, 2017 | Las Vegas, USA}

Antibody development updates for users of bio-layer interferometry kinetics comparison to SPR and high-throughput quantitation of bioprocess residuals

Jeff Mihailoff Pall ForteBio LLC, USA

Pall Fortebio's Bio-Layer Interferometry has been utilized by the antibody biopharma market since its inception in 2005. This gamechanging technology allowed scientists to bypass ELISA and HPLC technologies for antibody quantification. In addition, its lower price point and easy of use allowed it to be a substitute for Surface Plasmon Resonance (SPR) studies on antibody-antigen binding affinity. However, there have remained questions about the accuracy of the work as related to SPR. In this talk, the author will review a recent large-scale study in which different variables related to assay design were tested and then compared to SPR studies. Finally, the author will review some of the newer technology changes and how they are being applied to bioprocess residuals quantification.

Biography

Jeff Mihailoff has an MS in Molecular Biology and MBA from the University of Florida. Since leaving academia, he has been selling research tools into the Biopharma and Academic research market. Prior to ForteBio, he was the bioprocess and chromatography specialist at GE Healthcare focused on downstream purification. He also has experience with multiple different bioanalytical techniques such as Surface Plasmon Resonance, Isothermal Titration Calorimetry, and HPLC. He and his wife enjoy scientific advancement and have dedicated their lives to assisting scientists in taking their technology to the next level.

jeff_mihailoff@pall.com

Notes: